Literature DB >> 15056846

2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents.

Makoto Koizumi1.   

Abstract

Novel 2'-O,4'-C-ethylene nucleosides have been synthesized as building blocks for antisense and antigene oligonucleotides. 2'-O,4'-C-Ethylene-bridged nucleic acids (ENA) comprising 2'-O,4'-C-ethylene nucleosides have considerable affinity to complementary RNA and double-stranded DNA. Incorporation of 2'-O,4'-C-ethylene nucleosides into oligonucleotides dramatically increase their resistance against exonucleases. In this review, the properties of ENA oligonucleotides and some of their applications as antisense and antigene oligonucleotides are described.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056846     DOI: 10.1248/bpb.27.453

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  3 in total

Review 1.  2'-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping.

Authors:  Tomoko Lee; Hiroyuki Awano; Mariko Yagi; Masaaki Matsumoto; Nobuaki Watanabe; Ryoya Goda; Makoto Koizumi; Yasuhiro Takeshima; Masafumi Matsuo
Journal:  Genes (Basel)       Date:  2017-02-10       Impact factor: 4.096

Review 2.  The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.

Authors:  Philipp Reautschnig; Paul Vogel; Thorsten Stafforst
Journal:  RNA Biol       Date:  2016-07-14       Impact factor: 4.652

3.  Renadirsen, a Novel 2'OMeRNA/ENA® Chimera Antisense Oligonucleotide, Induces Robust Exon 45 Skipping for Dystrophin In Vivo.

Authors:  Kentaro Ito; Hideo Takakusa; Masayo Kakuta; Akira Kanda; Nana Takagi; Hiroyuki Nagase; Nobuaki Watanabe; Daigo Asano; Ryoya Goda; Takeshi Masuda; Akifumi Nakamura; Yoshiyuki Onishi; Toshio Onoda; Makoto Koizumi; Yasuhiro Takeshima; Masafumi Matsuo; Kiyosumi Takaishi
Journal:  Curr Issues Mol Biol       Date:  2021-09-25       Impact factor: 2.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.